Tilki D, et al. - In this investigation, researchers ascertained if treatment of Gleason score 9-10 prostate cancer with androgen deprivation therapy (termed MaxRP) vs androgen deprivation therapy (termed MaxRT) was correlated with prostate cancer–specific mortality (PCSM) and all-cause mortality (ACM) risk. There were 639 men in the cohort, with an average age of 65.83 (6.52) years. Findings suggested that it is possible that treatment with MaxRP or MaxRT can lead to an equivalent risk of PCSM and ACM for men with biopsy Gleason score 9-10 prostate cancer.